Ardelyx Operating Margin from 2010 to 2024
| ARDX Stock | USD 5.25 0.06 1.13% |
Check Ardelyx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ardelyx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 9.3 M or Selling General Administrative of 141.1 M, as well as many indicators such as Price To Sales Ratio of 10.38, Dividend Yield of 0.0 or PTB Ratio of 8.56. Ardelyx financial statements analysis is a perfect complement when working with Ardelyx Valuation or Volatility modules.
Ardelyx | Operating Margin |
Latest Ardelyx's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Ardelyx over the last few years. It is Ardelyx's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ardelyx's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.02 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Ardelyx Operating Margin Regression Statistics
| Arithmetic Mean | (6.28) | |
| Coefficient Of Variation | (155.62) | |
| Mean Deviation | 7.24 | |
| Median | (1.63) | |
| Standard Deviation | 9.77 | |
| Sample Variance | 95.53 | |
| Range | 34.8362 | |
| R-Value | (0.23) | |
| Mean Square Error | 97.30 | |
| R-Squared | 0.05 | |
| Significance | 0.40 | |
| Slope | (0.51) | |
| Total Sum of Squares | 1,337 |
Ardelyx Operating Margin History
About Ardelyx Financial Statements
Ardelyx investors use historical fundamental indicators, such as Ardelyx's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Ardelyx. Please read more on our technical analysis and fundamental analysis pages.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Ardelyx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.